LaCalhene

About LaCalhene

LaCalhene operates in the Other / Uncategorized space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-11-18
  Lacalhene appoints new Chief Medical Officer ahead of pivotal trial
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• BioPharma Reporter · 2026-04-21
  Lacalhene signs supply agreement to support late-stage trials
  The work builds on more than a decade of radiochemistry collaboration.
• Reuters Health · 2026-01-16
  Lacalhene expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-10-07
  Lacalhene announces Phase II readout for lead theranostic candidate
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Nuclear Medicine Today · 2026-07-26
  Lacalhene files IND for next-generation PSMA-targeted agent
  The work builds on more than a decade of radiochemistry collaboration.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.